Universal Technical Institute, Inc.
Universal Technical Institute, Inc. (UTI) Stock Competitors & Peer Comparison
See (UTI) competitors and their performances in Stock Market.
Peer Comparison Table: Education & Training Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| UTI | $39.73 | -4.27% | 2.2B | 52.07 | $0.76 | N/A |
| EDU | $51.38 | -0.91% | 8.1B | 18.85 | $2.70 | +2.35% |
| TAL | $10.59 | -3.90% | 6.6B | 11.75 | $0.92 | N/A |
| GHC | $1,124.00 | +1.38% | 4.7B | 16.16 | $67.61 | +0.67% |
| LAUR | $32.84 | +1.07% | 4.5B | 17.18 | $1.87 | N/A |
| LOPE | $160.82 | +0.23% | 4.2B | 19.76 | $7.99 | N/A |
| ATGE | $106.64 | +1.49% | 3.9B | 15.71 | $6.79 | N/A |
| LRN | $89.85 | +1.63% | 3.8B | 13.81 | $6.39 | N/A |
| MH | $12.22 | +10.19% | 2.2B | -30.84 | -$0.37 | N/A |
| PRDO | $34.81 | -0.64% | 2.1B | 12.98 | $2.62 | +1.71% |
Stock Comparison
UTI vs EDU Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, EDU has a market cap of 8.1B. Regarding current trading prices, UTI is priced at $39.73, while EDU trades at $51.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas EDU's P/E ratio is 18.85. In terms of profitability, UTI's ROE is +0.13%, compared to EDU's ROE of +0.11%. Regarding short-term risk, UTI is more volatile compared to EDU. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check EDU's competition here
UTI vs TAL Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, TAL has a market cap of 6.6B. Regarding current trading prices, UTI is priced at $39.73, while TAL trades at $10.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas TAL's P/E ratio is 11.75. In terms of profitability, UTI's ROE is +0.13%, compared to TAL's ROE of +0.15%. Regarding short-term risk, UTI is more volatile compared to TAL. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check TAL's competition here
UTI vs GHC Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, GHC has a market cap of 4.7B. Regarding current trading prices, UTI is priced at $39.73, while GHC trades at $1,124.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas GHC's P/E ratio is 16.16. In terms of profitability, UTI's ROE is +0.13%, compared to GHC's ROE of +0.06%. Regarding short-term risk, UTI is more volatile compared to GHC. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check GHC's competition here
UTI vs LAUR Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, LAUR has a market cap of 4.5B. Regarding current trading prices, UTI is priced at $39.73, while LAUR trades at $32.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas LAUR's P/E ratio is 17.18. In terms of profitability, UTI's ROE is +0.13%, compared to LAUR's ROE of +0.25%. Regarding short-term risk, UTI is more volatile compared to LAUR. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check LAUR's competition here
UTI vs LOPE Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, LOPE has a market cap of 4.2B. Regarding current trading prices, UTI is priced at $39.73, while LOPE trades at $160.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas LOPE's P/E ratio is 19.76. In terms of profitability, UTI's ROE is +0.13%, compared to LOPE's ROE of +0.30%. Regarding short-term risk, UTI is less volatile compared to LOPE. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check LOPE's competition here
UTI vs ATGE Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, ATGE has a market cap of 3.9B. Regarding current trading prices, UTI is priced at $39.73, while ATGE trades at $106.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas ATGE's P/E ratio is 15.71. In terms of profitability, UTI's ROE is +0.13%, compared to ATGE's ROE of +0.17%. Regarding short-term risk, UTI is more volatile compared to ATGE. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check ATGE's competition here
UTI vs LRN Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, LRN has a market cap of 3.8B. Regarding current trading prices, UTI is priced at $39.73, while LRN trades at $89.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas LRN's P/E ratio is 13.81. In terms of profitability, UTI's ROE is +0.13%, compared to LRN's ROE of +0.20%. Regarding short-term risk, UTI is more volatile compared to LRN. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check LRN's competition here
UTI vs MH Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, MH has a market cap of 2.2B. Regarding current trading prices, UTI is priced at $39.73, while MH trades at $12.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas MH's P/E ratio is -30.84. In terms of profitability, UTI's ROE is +0.13%, compared to MH's ROE of -0.13%. Regarding short-term risk, UTI is less volatile compared to MH. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check MH's competition here
UTI vs PRDO Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, PRDO has a market cap of 2.1B. Regarding current trading prices, UTI is priced at $39.73, while PRDO trades at $34.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas PRDO's P/E ratio is 12.98. In terms of profitability, UTI's ROE is +0.13%, compared to PRDO's ROE of +0.17%. Regarding short-term risk, UTI is more volatile compared to PRDO. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check PRDO's competition here
UTI vs STRA Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, STRA has a market cap of 1.8B. Regarding current trading prices, UTI is priced at $39.73, while STRA trades at $80.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas STRA's P/E ratio is 13.95. In terms of profitability, UTI's ROE is +0.13%, compared to STRA's ROE of +0.08%. Regarding short-term risk, UTI is less volatile compared to STRA. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check STRA's competition here
UTI vs LINC Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, LINC has a market cap of 1.6B. Regarding current trading prices, UTI is priced at $39.73, while LINC trades at $49.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas LINC's P/E ratio is 68.19. In terms of profitability, UTI's ROE is +0.13%, compared to LINC's ROE of +0.12%. Regarding short-term risk, UTI is more volatile compared to LINC. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check LINC's competition here
UTI vs DAO Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, DAO has a market cap of 1.4B. Regarding current trading prices, UTI is priced at $39.73, while DAO trades at $12.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas DAO's P/E ratio is 93.46. In terms of profitability, UTI's ROE is +0.13%, compared to DAO's ROE of -0.05%. Regarding short-term risk, UTI is less volatile compared to DAO. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check DAO's competition here
UTI vs AFYA Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, AFYA has a market cap of 1.3B. Regarding current trading prices, UTI is priced at $39.73, while AFYA trades at $14.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas AFYA's P/E ratio is 8.22. In terms of profitability, UTI's ROE is +0.13%, compared to AFYA's ROE of +0.16%. Regarding short-term risk, UTI is more volatile compared to AFYA. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check AFYA's competition here
UTI vs PXED Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, PXED has a market cap of 1B. Regarding current trading prices, UTI is priced at $39.73, while PXED trades at $29.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas PXED's P/E ratio is 10.70. In terms of profitability, UTI's ROE is +0.13%, compared to PXED's ROE of +0.21%. Regarding short-term risk, UTI is more volatile compared to PXED. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check PXED's competition here
UTI vs APEI Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, APEI has a market cap of 978.1M. Regarding current trading prices, UTI is priced at $39.73, while APEI trades at $54.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas APEI's P/E ratio is 27.63. In terms of profitability, UTI's ROE is +0.13%, compared to APEI's ROE of +0.14%. Regarding short-term risk, UTI is more volatile compared to APEI. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check APEI's competition here
UTI vs ARCE Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, ARCE has a market cap of 927.4M. Regarding current trading prices, UTI is priced at $39.73, while ARCE trades at $13.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas ARCE's P/E ratio is -73.58. In terms of profitability, UTI's ROE is +0.13%, compared to ARCE's ROE of +0.02%. Regarding short-term risk, UTI is more volatile compared to ARCE. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check ARCE's competition here
UTI vs COUR Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, COUR has a market cap of 893.1M. Regarding current trading prices, UTI is priced at $39.73, while COUR trades at $5.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas COUR's P/E ratio is -13.88. In terms of profitability, UTI's ROE is +0.13%, compared to COUR's ROE of -0.10%. Regarding short-term risk, UTI is less volatile compared to COUR. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check COUR's competition here
UTI vs QSG Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, QSG has a market cap of 822.3M. Regarding current trading prices, UTI is priced at $39.73, while QSG trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas QSG's P/E ratio is 5.54. In terms of profitability, UTI's ROE is +0.13%, compared to QSG's ROE of +0.24%. Regarding short-term risk, UTI is less volatile compared to QSG. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check QSG's competition here
UTI vs REDU Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, REDU has a market cap of 730.3M. Regarding current trading prices, UTI is priced at $39.73, while REDU trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas REDU's P/E ratio is -23.04. In terms of profitability, UTI's ROE is +0.13%, compared to REDU's ROE of +0.15%. Regarding short-term risk, UTI is less volatile compared to REDU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check REDU's competition here
UTI vs GOTU Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, GOTU has a market cap of 688.2M. Regarding current trading prices, UTI is priced at $39.73, while GOTU trades at $1.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas GOTU's P/E ratio is -9.87. In terms of profitability, UTI's ROE is +0.13%, compared to GOTU's ROE of -0.21%. Regarding short-term risk, UTI is more volatile compared to GOTU. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check GOTU's competition here
UTI vs UDMY Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, UDMY has a market cap of 677.3M. Regarding current trading prices, UTI is priced at $39.73, while UDMY trades at $4.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas UDMY's P/E ratio is -92.60. In terms of profitability, UTI's ROE is +0.13%, compared to UDMY's ROE of -0.03%. Regarding short-term risk, UTI is more volatile compared to UDMY. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check UDMY's competition here
UTI vs KLC Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, KLC has a market cap of 475.5M. Regarding current trading prices, UTI is priced at $39.73, while KLC trades at $3.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas KLC's P/E ratio is -4.23. In terms of profitability, UTI's ROE is +0.13%, compared to KLC's ROE of -0.55%. Regarding short-term risk, UTI is less volatile compared to KLC. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check KLC's competition here
UTI vs VSTA Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, VSTA has a market cap of 394M. Regarding current trading prices, UTI is priced at $39.73, while VSTA trades at $4.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas VSTA's P/E ratio is 4.22. In terms of profitability, UTI's ROE is +0.13%, compared to VSTA's ROE of +0.10%. Regarding short-term risk, UTI is more volatile compared to VSTA. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check VSTA's competition here
UTI vs VTRU Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, VTRU has a market cap of 304.2M. Regarding current trading prices, UTI is priced at $39.73, while VTRU trades at $9.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas VTRU's P/E ratio is 15.91. In terms of profitability, UTI's ROE is +0.13%, compared to VTRU's ROE of +0.05%. Regarding short-term risk, UTI is more volatile compared to VTRU. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check VTRU's competition here
UTI vs LGCY Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, LGCY has a market cap of 151.9M. Regarding current trading prices, UTI is priced at $39.73, while LGCY trades at $11.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas LGCY's P/E ratio is 20.07. In terms of profitability, UTI's ROE is +0.13%, compared to LGCY's ROE of +0.60%. Regarding short-term risk, UTI is less volatile compared to LGCY. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check LGCY's competition here
UTI vs SKIL-WT Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, SKIL-WT has a market cap of 138.5M. Regarding current trading prices, UTI is priced at $39.73, while SKIL-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas SKIL-WT's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.13%, compared to SKIL-WT's ROE of -7.09%. Regarding short-term risk, UTI is less volatile compared to SKIL-WT. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check SKIL-WT's competition here
UTI vs CHGG Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, CHGG has a market cap of 114.8M. Regarding current trading prices, UTI is priced at $39.73, while CHGG trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas CHGG's P/E ratio is -1.30. In terms of profitability, UTI's ROE is +0.13%, compared to CHGG's ROE of -0.63%. Regarding short-term risk, UTI is less volatile compared to CHGG. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check CHGG's competition here
UTI vs YOUL Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, YOUL has a market cap of 67.5M. Regarding current trading prices, UTI is priced at $39.73, while YOUL trades at $0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas YOUL's P/E ratio is 9.87. In terms of profitability, UTI's ROE is +0.13%, compared to YOUL's ROE of +0.29%. Regarding short-term risk, UTI is less volatile compared to YOUL. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check YOUL's competition here
UTI vs BEDU Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, BEDU has a market cap of 66.8M. Regarding current trading prices, UTI is priced at $39.73, while BEDU trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas BEDU's P/E ratio is -0.55. In terms of profitability, UTI's ROE is +0.13%, compared to BEDU's ROE of +0.13%. Regarding short-term risk, UTI is more volatile compared to BEDU. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check BEDU's competition here
UTI vs SKIL Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, SKIL has a market cap of 58.3M. Regarding current trading prices, UTI is priced at $39.73, while SKIL trades at $6.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas SKIL's P/E ratio is -0.41. In terms of profitability, UTI's ROE is +0.13%, compared to SKIL's ROE of -7.09%. Regarding short-term risk, UTI is less volatile compared to SKIL. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check SKIL's competition here
UTI vs ONE Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, ONE has a market cap of 51.3M. Regarding current trading prices, UTI is priced at $39.73, while ONE trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas ONE's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.13%, compared to ONE's ROE of +2.36%. Regarding short-term risk, UTI is less volatile compared to ONE. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check ONE's competition here
UTI vs LFS Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, LFS has a market cap of 48.9M. Regarding current trading prices, UTI is priced at $39.73, while LFS trades at $1.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas LFS's P/E ratio is 17.00. In terms of profitability, UTI's ROE is +0.13%, compared to LFS's ROE of +0.47%. Regarding short-term risk, UTI is less volatile compared to LFS. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check LFS's competition here
UTI vs STG Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, STG has a market cap of 42.4M. Regarding current trading prices, UTI is priced at $39.73, while STG trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas STG's P/E ratio is 0.79. In terms of profitability, UTI's ROE is +0.13%, compared to STG's ROE of +0.44%. Regarding short-term risk, UTI is less volatile compared to STG. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check STG's competition here
UTI vs AIU Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, AIU has a market cap of 37.6M. Regarding current trading prices, UTI is priced at $39.73, while AIU trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas AIU's P/E ratio is 0.51. In terms of profitability, UTI's ROE is +0.13%, compared to AIU's ROE of -1.90%. Regarding short-term risk, UTI is less volatile compared to AIU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check AIU's competition here
UTI vs RYET Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, RYET has a market cap of 32.9M. Regarding current trading prices, UTI is priced at $39.73, while RYET trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas RYET's P/E ratio is -7.50. In terms of profitability, UTI's ROE is +0.13%, compared to RYET's ROE of -10.11%. Regarding short-term risk, UTI is less volatile compared to RYET. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check RYET's competition here
UTI vs YQ Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, YQ has a market cap of 24.1M. Regarding current trading prices, UTI is priced at $39.73, while YQ trades at $2.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas YQ's P/E ratio is -1.09. In terms of profitability, UTI's ROE is +0.13%, compared to YQ's ROE of -0.46%. Regarding short-term risk, UTI is less volatile compared to YQ. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check YQ's competition here
UTI vs GNS Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, GNS has a market cap of 20.2M. Regarding current trading prices, UTI is priced at $39.73, while GNS trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas GNS's P/E ratio is -0.45. In terms of profitability, UTI's ROE is +0.13%, compared to GNS's ROE of -0.37%. Regarding short-term risk, UTI is less volatile compared to GNS. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check GNS's competition here
UTI vs JZ Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, JZ has a market cap of 20.2M. Regarding current trading prices, UTI is priced at $39.73, while JZ trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas JZ's P/E ratio is -1.41. In terms of profitability, UTI's ROE is +0.13%, compared to JZ's ROE of -0.43%. Regarding short-term risk, UTI is less volatile compared to JZ. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check JZ's competition here
UTI vs AACG Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, AACG has a market cap of 18.7M. Regarding current trading prices, UTI is priced at $39.73, while AACG trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas AACG's P/E ratio is -5.34. In terms of profitability, UTI's ROE is +0.13%, compared to AACG's ROE of -0.89%. Regarding short-term risk, UTI is less volatile compared to AACG. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check AACG's competition here
UTI vs GEHI Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, GEHI has a market cap of 18.3M. Regarding current trading prices, UTI is priced at $39.73, while GEHI trades at $13.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas GEHI's P/E ratio is -0.24. In terms of profitability, UTI's ROE is +0.13%, compared to GEHI's ROE of -0.90%. Regarding short-term risk, UTI is less volatile compared to GEHI. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check GEHI's competition here
UTI vs IH Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, IH has a market cap of 17.1M. Regarding current trading prices, UTI is priced at $39.73, while IH trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas IH's P/E ratio is 6.38. In terms of profitability, UTI's ROE is +0.13%, compared to IH's ROE of +0.10%. Regarding short-term risk, UTI is more volatile compared to IH. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check IH's competition here
UTI vs EDTK Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, EDTK has a market cap of 15.9M. Regarding current trading prices, UTI is priced at $39.73, while EDTK trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas EDTK's P/E ratio is -12.50. In terms of profitability, UTI's ROE is +0.13%, compared to EDTK's ROE of -0.19%. Regarding short-term risk, UTI is more volatile compared to EDTK. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check EDTK's competition here
UTI vs TEDU Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, TEDU has a market cap of 12.2M. Regarding current trading prices, UTI is priced at $39.73, while TEDU trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas TEDU's P/E ratio is -2.40. In terms of profitability, UTI's ROE is +0.13%, compared to TEDU's ROE of -0.05%. Regarding short-term risk, UTI is less volatile compared to TEDU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check TEDU's competition here
UTI vs ASPU Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, ASPU has a market cap of 11M. Regarding current trading prices, UTI is priced at $39.73, while ASPU trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas ASPU's P/E ratio is -0.44. In terms of profitability, UTI's ROE is +0.13%, compared to ASPU's ROE of +0.19%. Regarding short-term risk, UTI is less volatile compared to ASPU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check ASPU's competition here
UTI vs BTCT Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, BTCT has a market cap of 10.6M. Regarding current trading prices, UTI is priced at $39.73, while BTCT trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas BTCT's P/E ratio is -1.42. In terms of profitability, UTI's ROE is +0.13%, compared to BTCT's ROE of -0.18%. Regarding short-term risk, UTI is more volatile compared to BTCT. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check BTCT's competition here
UTI vs VEDU Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, VEDU has a market cap of 9.3M. Regarding current trading prices, UTI is priced at $39.73, while VEDU trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas VEDU's P/E ratio is -1.91. In terms of profitability, UTI's ROE is +0.13%, compared to VEDU's ROE of -0.43%. Regarding short-term risk, UTI is less volatile compared to VEDU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check VEDU's competition here
UTI vs WAFU Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, WAFU has a market cap of 7.6M. Regarding current trading prices, UTI is priced at $39.73, while WAFU trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas WAFU's P/E ratio is -57.67. In terms of profitability, UTI's ROE is +0.13%, compared to WAFU's ROE of -0.01%. Regarding short-term risk, UTI is more volatile compared to WAFU. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check WAFU's competition here
UTI vs TCTM Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, TCTM has a market cap of 4.9M. Regarding current trading prices, UTI is priced at $39.73, while TCTM trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas TCTM's P/E ratio is -0.15. In terms of profitability, UTI's ROE is +0.13%, compared to TCTM's ROE of -0.01%. Regarding short-term risk, UTI is less volatile compared to TCTM. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check TCTM's competition here
UTI vs TWOU Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, TWOU has a market cap of 4.4M. Regarding current trading prices, UTI is priced at $39.73, while TWOU trades at $1.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas TWOU's P/E ratio is -0.01. In terms of profitability, UTI's ROE is +0.13%, compared to TWOU's ROE of -0.88%. Regarding short-term risk, UTI is less volatile compared to TWOU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check TWOU's competition here
UTI vs CLEU Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, CLEU has a market cap of 3.5M. Regarding current trading prices, UTI is priced at $39.73, while CLEU trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas CLEU's P/E ratio is -0.00. In terms of profitability, UTI's ROE is +0.13%, compared to CLEU's ROE of -0.08%. Regarding short-term risk, UTI is less volatile compared to CLEU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check CLEU's competition here
UTI vs METX Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, METX has a market cap of 3.1M. Regarding current trading prices, UTI is priced at $39.73, while METX trades at $2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas METX's P/E ratio is 0.79. In terms of profitability, UTI's ROE is +0.13%, compared to METX's ROE of -0.04%. Regarding short-term risk, UTI is less volatile compared to METX. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check METX's competition here
UTI vs EEIQ Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, EEIQ has a market cap of 2.4M. Regarding current trading prices, UTI is priced at $39.73, while EEIQ trades at $2.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas EEIQ's P/E ratio is -1.13. In terms of profitability, UTI's ROE is +0.13%, compared to EEIQ's ROE of -0.34%. Regarding short-term risk, UTI is less volatile compared to EEIQ. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check EEIQ's competition here
UTI vs FEDU Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, FEDU has a market cap of 2.3M. Regarding current trading prices, UTI is priced at $39.73, while FEDU trades at $10.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas FEDU's P/E ratio is 18.08. In terms of profitability, UTI's ROE is +0.13%, compared to FEDU's ROE of -0.00%. Regarding short-term risk, UTI is more volatile compared to FEDU. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check FEDU's competition here
UTI vs MYND Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, MYND has a market cap of 1.4M. Regarding current trading prices, UTI is priced at $39.73, while MYND trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas MYND's P/E ratio is -0.16. In terms of profitability, UTI's ROE is +0.13%, compared to MYND's ROE of -1.26%. Regarding short-term risk, UTI is less volatile compared to MYND. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check MYND's competition here
UTI vs RYB Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, RYB has a market cap of 1M. Regarding current trading prices, UTI is priced at $39.73, while RYB trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas RYB's P/E ratio is 1.87. In terms of profitability, UTI's ROE is +0.13%, compared to RYB's ROE of +0.05%. Regarding short-term risk, UTI is less volatile compared to RYB. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check RYB's competition here
UTI vs GV Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, GV has a market cap of 995.9K. Regarding current trading prices, UTI is priced at $39.73, while GV trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas GV's P/E ratio is -0.06. In terms of profitability, UTI's ROE is +0.13%, compared to GV's ROE of -1.38%. Regarding short-term risk, UTI is less volatile compared to GV. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check GV's competition here
UTI vs GSUN Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, GSUN has a market cap of 752.5K. Regarding current trading prices, UTI is priced at $39.73, while GSUN trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas GSUN's P/E ratio is -0.21. In terms of profitability, UTI's ROE is +0.13%, compared to GSUN's ROE of -1.90%. Regarding short-term risk, UTI is less volatile compared to GSUN. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check GSUN's competition here
UTI vs AMBO Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, AMBO has a market cap of 345.6K. Regarding current trading prices, UTI is priced at $39.73, while AMBO trades at $2.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas AMBO's P/E ratio is 5.15. In terms of profitability, UTI's ROE is +0.13%, compared to AMBO's ROE of +1.09%. Regarding short-term risk, UTI is less volatile compared to AMBO. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check AMBO's competition here
UTI vs KIDZW Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, KIDZW has a market cap of 198.7K. Regarding current trading prices, UTI is priced at $39.73, while KIDZW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas KIDZW's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.13%, compared to KIDZW's ROE of -3.99%. Regarding short-term risk, UTI is less volatile compared to KIDZW. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check KIDZW's competition here
UTI vs KIDZ Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, KIDZ has a market cap of 169.6K. Regarding current trading prices, UTI is priced at $39.73, while KIDZ trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas KIDZ's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.13%, compared to KIDZ's ROE of -3.99%. Regarding short-term risk, UTI is less volatile compared to KIDZ. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check KIDZ's competition here
UTI vs LXEH Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, LXEH has a market cap of 86K. Regarding current trading prices, UTI is priced at $39.73, while LXEH trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas LXEH's P/E ratio is -0.05. In terms of profitability, UTI's ROE is +0.13%, compared to LXEH's ROE of -0.20%. Regarding short-term risk, UTI is less volatile compared to LXEH. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check LXEH's competition here
UTI vs FCHL Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, FCHL has a market cap of 66.5K. Regarding current trading prices, UTI is priced at $39.73, while FCHL trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas FCHL's P/E ratio is -0.33. In terms of profitability, UTI's ROE is +0.13%, compared to FCHL's ROE of +2.18%. Regarding short-term risk, UTI is less volatile compared to FCHL. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check FCHL's competition here
UTI vs BTCTW Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, BTCTW has a market cap of 15.5K. Regarding current trading prices, UTI is priced at $39.73, while BTCTW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas BTCTW's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.13%, compared to BTCTW's ROE of -0.18%. Regarding short-term risk, UTI is less volatile compared to BTCTW. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check BTCTW's competition here
UTI vs RSHL Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, RSHL has a market cap of 0. Regarding current trading prices, UTI is priced at $39.73, while RSHL trades at N/A.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas RSHL's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.13%, compared to RSHL's ROE of N/A. Regarding short-term risk, Volatility data is not available for a full comparison. UTI has daily volatility of 3.50 and RSHL has daily volatility of N/A.Check RSHL's competition here
UTI vs TTEI Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, TTEI has a market cap of 0. Regarding current trading prices, UTI is priced at $39.73, while TTEI trades at N/A.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas TTEI's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.13%, compared to TTEI's ROE of -4.00%. Regarding short-term risk, Volatility data is not available for a full comparison. UTI has daily volatility of 3.50 and TTEI has daily volatility of N/A.Check TTEI's competition here
UTI vs ZME Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, ZME has a market cap of 0. Regarding current trading prices, UTI is priced at $39.73, while ZME trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas ZME's P/E ratio is -0.00. In terms of profitability, UTI's ROE is +0.13%, compared to ZME's ROE of -1.88%. Regarding short-term risk, UTI is less volatile compared to ZME. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check ZME's competition here
UTI vs ZVO Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, ZVO has a market cap of 0. Regarding current trading prices, UTI is priced at $39.73, while ZVO trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas ZVO's P/E ratio is -0.08. In terms of profitability, UTI's ROE is +0.13%, compared to ZVO's ROE of -1.07%. Regarding short-term risk, UTI is less volatile compared to ZVO. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check ZVO's competition here
UTI vs GPX Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, GPX has a market cap of 0. Regarding current trading prices, UTI is priced at $39.73, while GPX trades at $20.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas GPX's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.13%, compared to GPX's ROE of +0.03%. Regarding short-term risk, UTI is more volatile compared to GPX. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check GPX's competition here
UTI vs METXW Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, METXW has a market cap of 0. Regarding current trading prices, UTI is priced at $39.73, while METXW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas METXW's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.13%, compared to METXW's ROE of -0.18%. Regarding short-term risk, UTI is less volatile compared to METXW. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check METXW's competition here
UTI vs HMHC Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, HMHC has a market cap of 0. Regarding current trading prices, UTI is priced at $39.73, while HMHC trades at $21.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas HMHC's P/E ratio is 12.54. In terms of profitability, UTI's ROE is +0.13%, compared to HMHC's ROE of +0.01%. Regarding short-term risk, UTI is more volatile compared to HMHC. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check HMHC's competition here
UTI vs APOL Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, APOL has a market cap of 0. Regarding current trading prices, UTI is priced at $39.73, while APOL trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas APOL's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.13%, compared to APOL's ROE of -0.08%. Regarding short-term risk, UTI is more volatile compared to APOL. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check APOL's competition here
UTI vs HLG Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, HLG has a market cap of 0. Regarding current trading prices, UTI is priced at $39.73, while HLG trades at $14.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas HLG's P/E ratio is 5.29. In terms of profitability, UTI's ROE is +0.13%, compared to HLG's ROE of +0.11%. Regarding short-term risk, UTI is more volatile compared to HLG. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check HLG's competition here
UTI vs FHS Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, FHS has a market cap of 0. Regarding current trading prices, UTI is priced at $39.73, while FHS trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas FHS's P/E ratio is 0.55. In terms of profitability, UTI's ROE is +0.13%, compared to FHS's ROE of N/A. Regarding short-term risk, UTI is less volatile compared to FHS. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check FHS's competition here
UTI vs NEW Comparison May 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 2.2B. In comparison, NEW has a market cap of 0. Regarding current trading prices, UTI is priced at $39.73, while NEW trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 52.07, whereas NEW's P/E ratio is -0.55. In terms of profitability, UTI's ROE is +0.13%, compared to NEW's ROE of -0.09%. Regarding short-term risk, UTI is less volatile compared to NEW. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check NEW's competition here